Goodwin Advised Third Rock Ventures, Co-Lead Investor on the $165 Million Series A Financing to Launch Syremis Therapeutics
Goodwin Advised Third Rock Ventures, Co-Lead Investor on the $165 Million Series A Financing to Launch Syremis Therapeutics
The Global law firm, Goodwin Life Sciences team advised Third Rock Ventures in connection with the $165 million Series A financing launch of Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel treatments for serious mental health conditions. The Series A was co-led by Third Rock Ventures and Dexcel Pharma, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet. The funds will support the advancement of Syremis’ pipeline through clinical proof of concept.
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients. By starting with big ideas and fostering collaboration among people with expertise in science, medicine, business and strategy, we aim to discover, launch and build innovative companies that can transform the lives of patients. Our mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve.
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA antagonism. Syremis’ lead program, ST-905, is a dual M1/M4 agonist in Phase 1 development for schizophrenia and other psychiatric conditions.
The Goodwin deal team was led by Mayan Katz (Partner) and Jennifer Ford (Counsel) and included Kingsley Taft (Partner), Sari Lerner (Associate), Amit Avram (Associate), Catherine McCarty (Partner) and Emily Rapalino (Partner).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
